Sector News

Allergan inks $90 million deal for Anterios

January 7, 2016
Life sciences

Allergan PLC, which last year agreed to merge with Pfizer Inc., on Thursday said it will buy clinical-stage pharmaceutical company Anterios Inc.

Under the terms of the deal, Allergan will pay Anterios $90 million up front, plus milestone payments.

Anterios is the developer of NDS, a technology that delivers neurotoxins through the skin instead of through injection. Allergan is perhaps best known as the maker of Botox, a neurotoxin with both cosmetic and therapeutic variations used to treat everything from wrinkles to osteoarthritis.

In a news release, Allergan Executive Vice President David Nicholson said the deal allows Allergan to advance “a new delivery system and formulations that are appealing to both patients and physicians.”

Allergan also will get global rights to ANT-1207, a topical drug being investigated for the use of excessive sweating, acne and crow’s feet.

Allergan in November agreed to a more than $150 billion tie-up with Pfizer, a historic merger that would create the world’s biggest drugmaker. The combined company will have top-selling products including Pfizer’s Prevnar pneumonia vaccine and Allergan’s Botox, and an industry-topping R&D budget.

By Chelsey Dulaney

Source: Wall Street Journal

Join the discussion!

Your email address will not be published. Required fields are marked *

Related News

November 22, 2020

Belgium is ‘European biotech leader’ for 3rd year in a row

Life sciences

Belgian companies account for just under a quarter (24%) of the total stock market value of all public biotech companies in Europe.

November 22, 2020

J&J, following BMS, pledges $100M to address racism and health inequities

Life sciences

Johnson & Johnson is re-upping its commitment to addressing health inequities as the pandemic lays bare long-standing divisions.

November 22, 2020

Sanofi sponsors Parkinson’s Foundation’s genetic study with $1M for free testing

Life sciences

It’s estimated that 10% to 15% of people with Parkinson’s have a genetic form of the disease and Sanofi Genzyme is backing a new study to help find those people.

Send this to a friend